Rosuvastatin vs Trenbolone
FDA Approved vs Moderate Research
avoid Mechanism-based · 64% Both Rosuvastatin and Trenbolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Rosuvastatin Trenbolone
Weight 481.54 Da 270.37 Da (base)
Half-life ~19 hours ~3 days (acetate)
Type Synthetic statin (C22H28FN3O6S-Ca) 19-nortestosterone derivative (C18H22O2), trienone steroid
Key Benefits
Rosuvastatin
01 Most potent statin available, with LDL reductions of 45-63% depending on dose
02 Long half-life (19 hours) allows flexible once-daily dosing at any time of day
03 Effective at counteracting AAS-induced lipid disturbances, particularly elevated LDL
04 Significant reduction in high-sensitivity CRP (30-50%), indicating anti-inflammatory benefit
05 Hydrophilic structure provides hepatic selectivity with potentially fewer muscle side effects
06 Raises HDL cholesterol by 8-14%, partially offsetting AAS-mediated HDL suppression
07 Proven cardiovascular event and mortality reduction in large-scale clinical trials
08 Reduces triglycerides by 10-35%, beneficial during bulking phases or when using compounds that elevate TG
Trenbolone
01 Exceptional lean muscle mass accrual with minimal water retention due to non-aromatizing profile
02 Dramatic body recomposition capability -- simultaneous muscle gain and fat loss even in caloric deficit
03 Approximately five times the anabolic and androgenic potency of testosterone (500:500 ratio)
04 Powerful anti-catabolic effects through glucocorticoid receptor antagonism, protecting muscle during dieting
05 Significant increases in strength across all compound movements, often rapid in onset
06 Enhanced nutrient partitioning, directing calories toward lean tissue accretion over fat storage
07 Pronounced muscle hardness, density, and vascularity due to absence of estrogenic water retention
08 Increased IGF-1 production in muscle tissue, amplifying growth signaling pathways
Dosing Protocols
Rosuvastatin
5-20 mg/day / Once daily
Trenbolone
200-400 mg/week / Every other day (acetate) or 2x per week (enanthate)
Recomposition - Moderate (Acetate) 200-300 mg/week (50-75 mg every other day) Every other day
Advanced Cutting (Acetate) 300-400 mg/week (75-100 mg every other day) Every other day
Lean Bulk (Enanthate) 200-400 mg/week 2x per week
Contest Preparation - Advanced 300-500 mg/week Every other day (acetate) or 2x per week (enanthate)
Side Effects
Rosuvastatin
Muscle pain and myalgia (5-10% of users) -- the most frequently reported complaint, ranging from mild soreness to significant discomfort
Headache
Nausea and abdominal discomfort
Weakness or fatigue
Constipation or diarrhea
Trenbolone
Insomnia and severely disrupted sleep architecture (one of the most universally reported side effects, affecting the majority of users)
Night sweats, often drenching, requiring sheet changes
Significantly reduced cardiovascular endurance and aerobic capacity
Increased aggression, irritability, and shortened temper
Anxiety and restlessness, particularly at higher doses
Tren cough: acute, intense coughing fit lasting 30-90 seconds immediately after injection, caused by a small amount of oil entering a blood vessel
Dark-colored urine (oxidized metabolites; not necessarily indicative of kidney damage but should be monitored)
Elevated body temperature and increased sweating throughout the day
Acne and oily skin, particularly on shoulders, back, and chest
Accelerated hair loss in those genetically predisposed to male pattern baldness
Profoundly suppressive of natural testosterone production (near-complete HPT axis shutdown)
Increased heart rate and elevated blood pressure
Contraindications
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to rosuvastatin or any excipients
Pregnancy and breastfeeding (Category X -- statins are teratogenic)
Concomitant use with cyclosporine (at all doses of rosuvastatin)
Severe renal impairment (eGFR <30 mL/min) for doses above 10 mg
First steroid cycle or limited anabolic steroid experience (trenbolone is strictly an advanced-only compound)
Pre-existing cardiovascular disease, cardiomyopathy, or significant cardiac risk factors
History of mental health conditions: anxiety disorders, depression, bipolar disorder, or psychotic episodes
Liver disease or significantly elevated liver enzymes
Kidney disease or impaired renal function
Uncontrolled hypertension
Polycythemia (hematocrit above 54% at baseline)
Prostate cancer or history of hormone-sensitive cancers
Active or recent substance abuse (trenbolone's psychological effects can exacerbate addictive behaviors)
Pregnancy or potential for pregnancy in female partners (extremely virilizing compound)
Research Evidence
Rosuvastatin Trenbolone
Status FDA Approved Moderate Research
References 4 studies 5 studies
Latest 2023 January 2023
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.